Lionco: Subsidiary Lionco Pharmaceutical's product, injectable cefazolin sodium, is expected to be selected for national centralized drug procurement

Zhitong
2025.10.29 07:58

Lionco announced that its wholly-owned subsidiary, Lionco Pharmaceutical, participated in the 11th national centralized procurement organized by the National Organization for Drug Procurement Office, and its product, injectable cefazolin sodium, is expected to be selected. The sales revenue of this product in 2024 is projected to be 23.0089 million yuan, accounting for 6.06% of the company's operating income for 2024. If selected and a purchase and sales contract is signed and implemented, it will promote the market expansion of the company's related products and enhance brand influence, positively impacting future performance. However, there is currently uncertainty regarding the signing of contracts and other follow-up matters, and the company will closely monitor progress and fulfill its information disclosure obligations

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer